1,102 results

#135424-AAV1

Ready-to-use AAV1 particles produced from pAAV-syn-jYCaMP1s (#135424). In addition to the viral particles, you will also receive purified pAAV-syn-jYCaMP1s plasmid DNA. Synapsin-driven expression of calcium sensor YCaMP1s. These AAV preparations are suitable purity for injection into animals.

Kaspar Podgorski

Mohr et al Nat Methods. 2020 May 25. pii: 10.1038/s

July 22, 2020

Academic Institutions and Nonprofits only

#225708-AAV9

Ready-to-use AAV9 particles produced from pAAV-EF1a-Dio-ASAP5-Kv2.1-WPRE (#225708). In addition to the viral particles, you will also receive purified pAAV-EF1a-Dio-ASAP5-Kv2.1-WPRE plasmid DNA. EF1a-driven, Cre-dependent soma-targeted expression of genetically encoded voltage indicator ASAP5. These AAV preparations are suitable purity for injection into animals.

Michael Lin

Hao et al Neuron. 2024 Sep 17:S0896-6273(24)00643-

Sept. 22, 2025

Academic Institutions and Nonprofits only

#100845-AAV5

Ready-to-use AAV5 particles produced from pAAV.Syn.Flex.GCaMP6s.WPRE.SV40 (#100845). In addition to the viral particles, you will also receive purified pAAV.Syn.Flex.GCaMP6s.WPRE.SV40 plasmid DNA. Syn-driven, Cre-dependent GCaMP6s calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

March 16, 2018

Academic Institutions and Nonprofits only

#105553-AAV8

Ready-to-use AAV8 particles produced from pENN.AAV.hSyn.Cre.WPRE.hGH (#105553). In addition to the viral particles, you will also receive purified pENN.AAV.hSyn.Cre.WPRE.hGH plasmid DNA. hSyn-driven Cre expression. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

March 12, 2021

Academic Institutions and Nonprofits only

#100857-AAV1

Ready-to-use AAV1 particles produced from pAAV.Syn.NES-jRGECO1b.WPRE.SV40 (#100857). In addition to the viral particles, you will also receive purified pAAV.Syn.NES-jRGECO1b.WPRE.SV40 plasmid DNA. Syn-driven jRGECO1b calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Dana et al eLife. 2016 Mar 24;5. pii: e12727. doi:

May 18, 2018

Academic Institutions and Nonprofits only

#137120-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-Con/Foff 2.0-GCaMP6M (#137120). In addition to the viral particles, you will also receive purified pAAV-Ef1a-Con/Foff 2.0-GCaMP6M plasmid DNA. EF1a-driven expression of GCaMP6m in the presence of Cre recombinase (inhibited in the presence of Flp recombinase). These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Nov. 23, 2020

Academic Institutions and Nonprofits only

#105532-AAV8

Ready-to-use AAV8 particles produced from pAAV.CMV.ffLuciferase.SV40 (#105532). In addition to the viral particles, you will also receive purified pAAV.CMV.ffLuciferase.SV40 plasmid DNA. CMV-driven ffLuciferase control. These AAV preparations are suitable purity for injection into animals.

James M. Wilson

June 29, 2018

Academic Institutions and Nonprofits only

#100835-AAV9

Ready-to-use AAV9 particles produced from pAAV.CAG.Flex.GCaMP6f.WPRE.SV40 (#100835). In addition to the viral particles, you will also receive purified pAAV.CAG.Flex.GCaMP6f.WPRE.SV40 plasmid DNA. CAG-driven, Cre-dependent GCaMP6f calcium sensor. These AAV preparations are suitable purity for injection into animals.

Douglas Kim, GENIE Project

Chen et al Nature. 2013 Jul 18;499(7458):295-300. d

May 11, 2018

Academic Institutions and Nonprofits only

#55641-AAV8

Ready-to-use AAV8 particles produced from pAAV-Ef1a-fDIO EYFP (#55641). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO EYFP plasmid DNA. EF1a-driven, Flp-dependent expression of EYFP. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Dec. 18, 2024

Academic Institutions and Nonprofits only

#75033-AAV1

Ready-to-use AAV1 particles produced from pAAV CD68-hM4D(Gi)-mCherry (#75033). In addition to the viral particles, you will also receive purified pAAV CD68-hM4D(Gi)-mCherry plasmid DNA. CD68-driven hM4D(Gi) receptor with an mCherry reporter for CNO-induced microglial inhibition. These AAV preparations are suitable purity for injection into animals.

Bryan Roth

Grace et al Proc Natl Acad Sci U S A. 2016 Jun 14;11

March 27, 2019

Academic Institutions and Nonprofits only

#191706-PHPeB

Ready-to-use AAV PHP.eB particles produced from AiP13044 - pAAV-AiE0779m_3xC2-minBG-SYFP2-WPRE3-BGHpA (Alias: CN3044) (#191706). In addition to the viral particles, you will also receive purified AiP13044 - pAAV-AiE0779m_3xC2-minBG-SYFP2-WPRE3-BGHpA (Alias: CN3044) plasmid DNA. SYFP2-expression in striatal direct pathway medium spiny neurons (D1-MSNs). These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Allen Institute for Brain Science, Jonathan Ting

Hunker et al Neuron. 2025 May 21;113(10):1507-1524.e1

July 15, 2024

Academic Institutions and Nonprofits only

#198513-AAV5

Ready-to-use AAV5 particles produced from pAAV_hSyn-PdCO-EGFP-WPRE (#198513). In addition to the viral particles, you will also receive purified pAAV_hSyn-PdCO-EGFP-WPRE plasmid DNA. Synapsin-driven expression of the optimized opsin PdCO in frame with EGFP. These AAV preparations are suitable purity for injection into animals.

Ofer Yizhar

Wietek et al Nat Methods. 2024 May 29. doi: 10.1038/s

April 10, 2024

Academic Institutions and Nonprofits only

#213944-PHPeB

Ready-to-use AAV PHP.eB particles produced from pAAV_BiSSTe4_dTomato_nlsdTomato (#213944). In addition to the viral particles, you will also receive purified pAAV_BiSSTe4_dTomato_nlsdTomato plasmid DNA. Bicistronic expression of dTomato and nuclear-targeted dTomato under the control of the SST interneuron-targeting enhancer E4. These AAV were produced with the PHPeB serotype, which permits efficient transduction of the central nervous system. These AAV preparations are suitable purity for injection into animals.

Gordon Fishell

Furlanis et al Neuron. 2025 May 21;113(10):1525-1547.e1

Dec. 2, 2024

Academic Institutions and Nonprofits only

#175181-AAV1

Ready-to-use AAV1 particles produced from pAAV.hSyn.FLEX.iGluSnFR3.v857.GPI.codonopt (#175181). In addition to the viral particles, you will also receive purified pAAV.hSyn.FLEX.iGluSnFR3.v857.GPI.codonopt plasmid DNA. Synapsin-driven, Cre-dependent, third generation glutamate sensor iGluSnFR3, variant 857. These AAV preparations are suitable purity for injection into animals.

Kaspar Podgorski

Aggarwal et al Nat Methods. 2023 May 4. doi: 10.1038/s4

May 16, 2023

Academic Institutions and Nonprofits only

#55639-AAVrg

Ready-to-use AAV Retrograde particles produced from pAAV-Ef1a-fDIO hChR2(H134R)-EYFP (#55639). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO hChR2(H134R)-EYFP plasmid DNA. Ef1a-driven, Flp-dependent expression of ChR2(H134R)-EYFP. These AAV were produced with a retrograde serotype, which permits retrograde access to projection neurons. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Fenno et al Nat Methods. 2014 Jul;11(7):763-72. doi:

Feb. 7, 2025

Academic Institutions and Nonprofits only

#100043-AAV9

Ready-to-use AAV9 particles produced from pAAV.synP.DIO.EGFP.WPRE.hGH (#100043). In addition to the viral particles, you will also receive purified pAAV.synP.DIO.EGFP.WPRE.hGH plasmid DNA. Synapsin-driven, Cre-dependent EGFP expression. These AAV preparations are suitable purity for injection into animals.

Ian Wickersham

April 20, 2018

Academic Institutions and Nonprofits only

#107312-AAV1

Ready-to-use AAV1 particles produced from AAV-hSyn-mCherry-P2A-Cre-WPRE (#107312). In addition to the viral particles, you will also receive purified AAV-hSyn-mCherry-P2A-Cre-WPRE plasmid DNA. hSyn-driven expression of mCherry and Cre (physically separate). These AAV preparations are suitable purity for injection into animals.

Hui Yang

Zhou et al Nat Neurosci. 2018 Jan 15. pii: 10.1038/

Oct. 28, 2021

Academic Institutions and Nonprofits only

#68720-AAV1

Ready-to-use AAV1 particles produced from pAAV-hSyn1-Flex-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA (#68720). In addition to the viral particles, you will also receive purified pAAV-hSyn1-Flex-mRuby2-GSG-P2A-GCaMP6s-WPRE-pA plasmid DNA. Cre-dependent GCaMP6s calcium sensor and bicistronic, physically separate mRuby2 expression under a human synapsin1 promoter. These AAV preparations are suitable purity for injection into animals.

Tobias Bonhoeffer, Mark Huebener, Tobias Rose

Rose et al Science. 2016 Jun 10;352(6291):1319-22.

March 7, 2018

Academic Institutions and Nonprofits only

#114471-AAV9

Ready-to-use AAV9 particles produced from pAAV-Ef1a-fDIO mCherry (#114471). In addition to the viral particles, you will also receive purified pAAV-Ef1a-fDIO mCherry plasmid DNA. Ef1a-driven, Flp recombinase-dependent expression of mCherry. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth

Aug. 28, 2020

Academic Institutions and Nonprofits only

#137152-AAV8

Ready-to-use AAV8 particles produced from pAAV-nEF-Con/Fon-NpHR3.3-EYFP (#137152). In addition to the viral particles, you will also receive purified pAAV-nEF-Con/Fon-NpHR3.3-EYFP plasmid DNA. nEF-driven, Cre and Flp-dependent expression of NpHR3.3-EYFP for optogenetic inhibition. These AAV preparations are suitable purity for injection into animals.

Karl Deisseroth, INTRSECT 2.0 Project

Fenno et al Neuron. 2020 Jun 20. pii: S0896-6273(20)

Feb. 25, 2021

Academic Institutions and Nonprofits only